Guanidinothiazole compounds, process for preparation and gastric inhibiting compositions containing them

• US 4,283,408 A
• Filed: 12/27/1979
• Issued: 08/11/1981
• Est. Priority Date: 08/02/1979
• Status: Expired due to Term

• Current Assignee: Yamanouchi Pharmaceutical Co., Ltd. (Astellas Pharma Incorporated)
• Original Assignee: Yamanouchi Pharmaceutical Co., Ltd. (Astellas Pharma Incorporated)
• Inventors: Ishii, Yoshio, Yanagisawa, Isao, Takeda, Masaaki, Isomura, Yasuo, Hirata, Yasufumi, Ito, Noriki, Tsukamoto, Shinichi
• Primary Examiner(s): Berch, Mark L.
• Application Number:
  US06/107,629
• Time in Patent Office: 593 Days
• Field of Search: 548/197, 424/270
• US Class Current: 514/370
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 277/40 Unsubstituted amino or imino radicals
• CPC Class Codes: C07D 277/48 by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines

Abstract

Novel guanidinothiazole compounds of the general formula ##STR1## wherein R represents a hydrogen atom or a lower alkyl group, R₁ represents an amino group, a lower alkyl group, a halogeno lower alkyl group, a substituted- or unsubstituted-aryl group, a mono- or di-lower alkylamino group, an arylamino group or an aralkylamino group, R₂ represents a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, Y represents a sulfur atom or a methylene group, m and n, each represents an integer of 1-3, and the pharmacologically acceptable acid addition salts thereof, they are useful as gastric acid secretion inhibitors.

Claims

1. Guanidinothiazole compounds of the formula ##STR34## wherein R represents a hydrogen atom or a lower alkyl group, R₁ represents an amino group, a lower alkyl group, a halogeno lower alkyl group, a phenyl or naphthyl group which is unsubstituted or substituted by halogen, hydroxyl, amino, or alkoxy, a mono- or di-lower alkylamino group, an arylamino group or an aralkylamino group, R₂ represents a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, Y represents a sulfur atom or a methylene group, m and n, each represents an integer of 1-3, and the pharmacologically acceptable acid addition salts thereof.

2. The compounds as claimed in claim 1 wherein R and R₂ are hydrogen atoms, R₁ is an amino group and Y is a sulfur atom.

3. The compounds as claimed in claim 1 wherein R₂ is a hydrogen atom or a lower alkyl group.

4. The compound as claimed in claim 1 which is N-sulfamoyl-3-[(2-guanidinothiazol-4-yl)methylthio]propionamidine.

5. The compound as claimed in claim 1 which is N-methansulfonyl-3-[(2-guanidinothiazol-4-yl)methylthio]propionamidine.

6. Medical composition containing a gastric acid secretion inhibiting amount of a guanidinothiazole compound of the formula ##STR35## wherein R represents a hydrogen atom or a lower alkyl group, R₁ represents an amino group, a lower alkyl group, a halogeno lower alkyl group, a phenyl or naphthyl group which is unsubstituted or substituted by halogen, hydroxyl, amino, or akoxy, a mono- or di-lower alkylamino group, an arylamino group or an aralkylamino group, R₂ represents a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, Y represents a sulfur atom or a methylene group, m and n, each represent an integer of 1-3, or a non-toxic acid addition salt thereof and pharmaceutically acceptable carriers or diluents.